Pharmacodynamics of aerosolized fosfomycin and amikacin against resistant clinical isolates of pseudomonas aeruginosa and klebsiella pneumoniae in a hollow-fiber infection model: Experimental basis for combination therapy

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 1, 2017, Pages

  Sime, Fekade Bruck ^a,b   Johnson, Adam ^b   Whalley, Sarah ^b   Santoyo Castelazo, Anahi ^b   Montgomery, A Bruce ^c   Walters, Kathie Ann ^c   Lipman, Jeffrey ^a   Hope, William W ^b   Roberts, Jason A ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c Cardeas Pharma   (United States)

Author keywords

Multidrug resistance; Nebulized; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMIKACIN; FOSFOMYCIN; AEROSOL; ANTIINFECTIVE AGENT;

AEROSOL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BACTERIUM ISOLATE; COLONY FORMING UNIT; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG DETERMINATION; DRUG HALF LIFE; EPITHELIAL LINING FLUID; GENE AMPLIFICATION; HOLLOW FIBER; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE INFECTION; MONOTHERAPY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; QUANTITATIVE ANALYSIS; VENTILATOR ASSOCIATED PNEUMONIA; BACTERIAL COUNT; BIOLOGICAL MODEL; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG POTENTIATION; GROWTH, DEVELOPMENT AND AGING; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; RESPIRATORY MUCOSA;

AEROSOLS; AMIKACIN; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FOSFOMYCIN; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY MUCOSA;

EID: 85009266759     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01763-16     Document Type: Article

References (20)

1. Rodvold KA, Yoo L, George JM. 2011. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents. Clin Pharmacokinet 50:1-8. https://doi.org/10.2165/11592900-000000000-00000.
2. Jamal JA, Abdul-Aziz MH, Lipman J, Roberts JA. 2013. Defining antibiotic dosing in lung infections. Clin Pulm Med 20:121-128. https://doi.org/10.1097/CPM.0b013e31828fc646.
3. Quon BS, Goss CH, Ramsey BW. 2014. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc 11:425-434. https://doi.org/10.1513/AnnalsATS.201311-395FR.
4. Kollef MH, Hamilton CW, Montgomery AB. 2013. Aerosolized antibiotics: do they add to the treatment of pneumonia? Curr Opin Infect Dis 26:538-544. https://doi.org/10.1097/QCO.0000000000000004.
5. Montgomery AB, Vallance S, Abuan T, Tservistas M, Davies A. 2014. A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow inline nebulizer system in mechanically ventilated patients. J Aerosol Med Pulm Drug Deliv 27:441-448. https://doi.org/10.1089/jamp.2013.1100.
6. Bassetti M, Luyt CE, Nicolau DP, Pugin J. 2016. Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. Ann Intensive Care 6:35. https://doi.org/10.1186/s13613-016-0140-x.
7. Niederman MS, Chastre J, Corkery K, Fink JB, Luyt CE, Garcia MS. 2012. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med 38:263-271. https://doi.org/10.1007/s00134-011-2420-0.
8. Poole K. 2005. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 49:479-487. https://doi.org/10.1128/AAC.49.2.479-487.2005.
9. Kahan FM, Kahan JS, Cassidy PJ, Kropp H. 1974. The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci 235:364-386. https://doi.org/10.1111/j.1749-6632.1974.tb43277.x.
10. MacLeod DL, Velayudhan J, Kenney TF, Therrien JH, Sutherland JL, Barker LM, Baker WR. 2012. Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa. Antimicrob Agents Chemother 56:1529-1538. https://doi.org/10.1128/AAC.05958-11.
11. Docobo-Perez F, Drusano GL, Johnson A, Goodwin J, Whalley S, Ramos-Martin V, Ballestero-Tellez M, Rodriguez-Martinez JM, Conejo MC, van Guilder M, Rodriguez-Bano J, Pascual A, Hope WW. 2015. Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance. Antimicrob Agents Chemother 59:5602-5610. https://doi.org/10.1128/AAC.00752-15.
12. Walsh CC, McIntosh MP, Peleg AY, Kirkpatrick CM, Bergen PJ. 2015. In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother 70:3042-3050. https://doi.org/10.1093/jac/dkv221.
13. Karageorgopoulos DE, Wang R, Yu XH, Falagas ME. 2012. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother 67:255-268. https://doi.org/10.1093/jac/dkr466.
14. CLSI. 2014. Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
15. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). 2003. Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution. Clin Microbiol Infect 9:ix-xv. https://doi.org/10.1046/j.1469-0691.2003.00790.x.
16. Cadwell JJS. 2012. The hollow fiber infection model for antimicrobial pharmacodynamics and pharmacokinetics. Adv Pharmacoepidem Drug Safety S1:007.
17. Blaser J. 1985. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J Antimicrob Chemother 15(Suppl A):125-130. https://doi.org/10.1093/jac/15.suppl-A.125.
18. Mahmoudi L, Mohammadpour AH, Ahmadi A, Niknam R, Mojtahedzadeh M. 2013. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients. Eur Rev Med Pharmacol Sci 17:285-291.
19. Parker S, Lipman J, Koulenti D, Dimopoulos G, Roberts JA. 2013. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. Int J Antimicrob Agents 42:289-293. https://doi.org/10.1016/j.ijantimicag.2013.05.018.
20. Center for Drug Evaluations and Research. 2001. Guidance for industry: bioanalytical method validation. U.S. Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf.